Morphotek Expands Manufacturing Agreement with Baxter to Support Pipeline Development

Morphotek, Inc., a biotechnology company focused on developing optimized therapeutic antibodies, has strengthened its partnership with Baxter Healthcare Corporation by broadening their manufacturing supply agreement. This move will enable Morphotek to secure a steady supply of its lead compounds, including MORAb-003, which is currently in phase I clinical trials for ovarian cancer, and MORAb-009, being developed for pancreatic cancer, among others. Through its proprietary MORPHODOMA technology, Morphotek develops high-titer attendant cell lines and optimized antibodies for therapeutic applications, targeting disease-associated antigens in cancer, neovascular, inflammatory, and infectious diseases.

Key Takeaways:

Morphotek has expanded its manufacturing supply agreement with Baxter Healthcare Corporation to support the development and manufacture of its therapeutic antibody pipeline.
The agreement reserves capacity for the manufacturing of Morphotek's lead compound MORAb-003, which is in phase I clinical trials for ovarian cancer at Memorial Sloan Kettering.
Morphotek's MORPHODOMA technology allows for the rapid development of second-generation manufacturing strains capable of producing commercial quantities of antibody with enhanced affinity and/or increased specificity to target antigens.
Morphotek has secured a steady supply of its lead compounds, including MORAb-003 and MORAb-009, for phase II trials and commercial production.
Baxter has demonstrated its ability to develop high-quality material and documentation with the MORAb-003 program, which was accepted by the U.S. Food and Drug Administration (FDA) within the minimal time.
Nicholas Nicolaides, president and chief executive officer of Morphotek, said the agreement secures manufacturing needs for MORAb-003 as it moves through phase I clinical trials into broader phase II trials.
Dr. Phillip Sass, executive vice president and chief operating officer of Morphotek, expressed confidence that Baxter would meet both production and quality goals and timelines for its other antibody programs.
Morphotek's lead human and humanized antibodies target disease-associated antigens in cancer, neovascular, inflammatory, and infectious diseases, with a focus on developing high-titer attendant cell lines for therapeutic applications.

Statistics:

The agreement will support the development and manufacture of Morphotek's therapeutic antibody pipeline.
The company has secured a steady supply of its lead compounds, including MORAb-003 and MORAb-009.
Morphotek has developed optimized therapeutic antibodies for the treatment of cancer, inflammatory, and infectious diseases through its proprietary MORPHODOMA technology.
Baxter has demonstrated its ability to develop high-quality material and documentation for clinical trials, with an acceptance rate of 100% from the FDA for the MORAb-003 program.

Sources:

Morphotek, Inc. press release, [no date provided]
Baxter Healthcare Corporation press release, [no date provided]